- United Technologies Corporation Professor in Cancer Research, Department of Immunobiology, Yale School of Medicine, Yale University
- Professor, Department of Dermatology, Yale School of Medicine, Yale University
- Professor, Department of Internal Medicine (Medical Oncology), Yale School of Medicine, Yale University
Dr. Lieping Chen is the United Technologies Corporation Professor in Cancer Research and Professor of Immunobiology, Dermatology, and Internal Medicine (Medical Oncology) at Yale University. He is an immunologist and physician-scientist whose research focuses on basic T cell biology and the translation of laboratory discoveries into clinical therapies, with a primary emphasis on cancer immunotherapy.
Dr. Chen’s laboratory is renowned for the 1999 discovery of the B7-H1 (PD-L1) molecule and the subsequent identification of the PD-1/PD-L1 pathway as a critical mechanism of immune evasion in the tumor microenvironment. This breakthrough was recognized as the number one Breakthrough of the Year by Science magazine in 2013 and led to the development of anti-PD-1/PD-L1 antibodies, now global standards of care for a broad spectrum of advanced cancers.
Before joining Yale, Dr. Chen held faculty positions at the Mayo Clinic and Johns Hopkins University, and scientist positions at Bristol-Myers Squibb. He is a prolific investigator with more than 400 peer-reviewed publications, a member of the National Academy of Sciences and the National Academy of Medicine, and a Fellow of the American Association for Cancer Research.